Abstract

You have accessJournal of UrologyTransplantation & Vascular Surgery: Renal Transplantation & Vascular Surgery II1 Apr 2016MP32-04 RENAL CELL CARCINOMA IN THE NATIVE KIDNEY IN DIALYSIS AND KIDNEY TRANSPLANT RECIPIENTS. COMPARISON OF PATHOLOGICAL FEATURES AND ACKD INFLUENCE. Kleiton Yamaçake, William Nahas, Ioannis Antonopoulos, Hideki Kanashiro, Raphael Kato, Renato Falci, and Affonso Piovesan Kleiton YamaçakeKleiton Yamaçake More articles by this author , William NahasWilliam Nahas More articles by this author , Ioannis AntonopoulosIoannis Antonopoulos More articles by this author , Hideki KanashiroHideki Kanashiro More articles by this author , Raphael KatoRaphael Kato More articles by this author , Renato FalciRenato Falci More articles by this author , and Affonso PiovesanAffonso Piovesan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1299AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Renal Cell Carcinoma (RCC) has a high incidence in patients with acquired cystic kidney disease (ACKD) due to hemodialysis. It has been reported that these tumors are less aggressive in RCC patients with normal renal function. We studied the clinical and pathologic outcomes of patients who developed RCC during dialysis and those who were diagnosed after transplantation. Groups were treated surgically for RCC in the native kidney METHODS Between January 1991 and December 2011, 2580 renal transplants were performed. Twenty-four patients underwent radical nephrectomy for a suspected renal mass in the native kidney. In 12 of these patients, the diagnosis and surgery were carried out prior to transplantation during the dialytic period (Group 1) and the remaining were carried out after transplantation (Group 2). In Group 2, 10 out of 12 patients with a suspected renal mass were confirmed to have RCC. One and 2 patients had bilateral disease in Group 1 and 2, respectively. This comprised 11 and 14 RCC in Groups 1 and 2, respectively. RESULTS Demographic data were similar in both groups. Mean period from transplant and radical nephrectomy in Group 1 was 97.6± 75.55(2-254) months. The mean duration of dialysis was higher in Group 1 (48.5± 15.7vs 26.22± 21.98, p= 0.147) and also had a higher association with ACKD (78.57% vs 18%, p= 0.0048). We observed a higher incidence of clear cell carcinoma in the dialytic group (92.7% vs 72.7%, p= 0.281). Papillary was present in 1 (Group 1) and 3 (Group 2) patients. Tumor multifocality occurred only in Group 1 (6 out of 14). The stage, Fuhrman grade, vascular invasion, necrosis, and size were similar in both groups. 13 RCC with ACKD were compared to 12 tumors without ACKD. There was no statistically difference regarding: age, gender, duration of dialisys, medical history, histology type, tumor size, stage, Fuhrman grade, vascular invasion and necrosis. Mean duration of dialysis was higher in patients with ACKD (48.2±44.09 vs 28.27±21.71 months, p= 0.3). Tumor multifocallity was observed only in patients with ACKD (p=0.0149). The mean follow up was 65.5± 42.31(8-156) months in Group 1 and 58± 42.51(2-145) months in Group 2. CONCLUSIONS Despite similar outcomes, it is clear that the renal masses that are acquired after renal transplantation have a different pathology than those acquired during dialysis. The low association with ACKD, low multiplicity and pathologic pattern are much more similar to normal kidney function tumors. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e429 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Kleiton Yamaçake More articles by this author William Nahas More articles by this author Ioannis Antonopoulos More articles by this author Hideki Kanashiro More articles by this author Raphael Kato More articles by this author Renato Falci More articles by this author Affonso Piovesan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.